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Vaccines against human papillomavirus (HPV) infection have the potential to reduce the
burden of cervical cancer. School-based delivery of HPV vaccines is cost-effective and suc-
cessful uptake depends on school teachers’ knowledge and acceptability of the vaccine.
The aim of this study is to assess primary school teachers’ knowledge and acceptability of
HPV vaccine and to explore facilitators and barriers of an ongoing Gavi Alliance-supported
vaccination program in Kitui County, Kenya.
Methods
This was a cross-sectional, mixed methods study in Central Division of Kitui County where
the Ministry of Health is offering the quadrivalent HPV vaccine to grade four girls. Data on
primary school teachers’ awareness, knowledge and acceptability of HPV vaccine as well
as facilitators and barriers to the project was collected through self-administered question-
naires and two focus group discussions.
Results
339 teachers (60% female) completed the survey (62% response rate) and 13 participated
in 2 focus group discussions. Vaccine awareness among teachers was high (90%), the
level of knowledge about HPV and cervical cancer among teachers was moderate (48%,
SD = 10.9) and females scored higher than males (50% vs. 46%, p = 0.002). Most teachers
(89%) would recommend the vaccine to their daughter or close relatives. Those who would
recommend the vaccine had more knowledge than those who would not (p = <0.001). The
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main barriers were insufficient information about the vaccine, poor accessibility of schools,
absenteeism of girls on vaccine days, and fear of side effects.
Conclusions
Despite low to moderate levels of knowledge about HPV vaccine among school teachers,
vaccine acceptability is high. Teachers with little knowledge on HPV vaccine are less likely
to accept the vaccine than those who know more; this may affect uptake if not addressed.
Empowering teachers to be vaccine champions in their community may be a feasible way of
disseminating information about HPV vaccine and cervical cancer.
Introduction
Human papillomavirus (HPV) is linked to the etiology of various cancers in humans, including
oral, pharyngeal, anal and genital cancers [1–4]. Key among these is cervical cancer, which is
due to persistent infection with oncogenic HPV genotypes in virtually all cases [5]. Cervical
cancer is the third most common cancer in women worldwide [6]. Each year, there are 530,000
cases and 275,000 deaths from cervical cancer globally [7]. Nearly 90% of these are in low-
income countries (LICs) [7] and it is the leading cause of cancer deaths in women in sub-Saha-
ran Africa (SSA) [8]. Eastern Africa has the highest burden of cervical cancer in the world, with
an age-standardized incidence ratio of 34.5 against an average of 9 per 100,000 in the developed
world [8]. In 2012, Kenya had 4,802 cases of cervical cancer, 51% of whom died [9].
Prophylactic vaccinations against HPV infection bear the potential to reduce the burden of
cervical cancer and have proven to be cost-effective when offered to women before infection
with HPV, especially in LICs where screening strategies are sub-optimal [10–12]. Currently,
there are three HPV vaccines that are safe and efficacious in preventing HPV infection: biva-
lent(Cervarix, GlaxoSmithKline), quadrivalent (Gardasil, Merck), and nonavalent (Gardasil,
Merck) HPV vaccines which protects against HPV 16 and 18; HPV 6, 11, 16 and 18; and HPV
6, 11, 16, 18, 31, 33, 45, 52 and 58, respectively [13]. HPV16 and 18 are the primary cause of
70% of all cervical cancers worldwide [14]. HPV 6 and 11 are present in over 90% of all ano-
genital warts [15].
Studies in SSA show high HPV vaccine acceptability [16–21] but only two countries,
Rwanda and recently, South Africa, have been able to roll out a national program [22,23]. To
date, at least five SSA countries—Cameroon, Kenya, Uganda, Lesotho, and Tanzania—have
piloted delivery of HPV vaccine to adolescent girls using different approaches [21,24–26].
Various avenues have been utilized to deliver HPV vaccine to targeted populations, includ-
ing schools, health-facilities and community outreach [16,20,22,24,27,28]. The school-based
approach has been shown to achieve high vaccine uptake in SSA [16,19,29]. Some countries
have also opted to combine the school-based approach with health facility or community out-
reach in order to broaden vaccine reach, especially for girls who are not enrolled in school
[21,22,30,31].
In a school-based approach, teachers play a pivotal role in HPV vaccine delivery. This
includes giving permission for use of school premises, educating parents and pupils on the vac-
cine and organization of vaccine days. Teachers' knowledge and attitude towards the vaccine
has been shown to significantly affect the success of school-based HPV vaccination programs
[32,33]. Disseminating the correct information about the vaccine is key in ensuring community
support. Erosion of public trust due to concerns about vaccine safety and future fertility as well
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as political and religious factors have slowed down vaccination in some countries like Rwanda
and Cameroon [20,21,34,35]. Similar concerns have even led to program suspension in other
countries such as Japan [36], India [37] and Canada [38].
For most SSA countries, cost has previously been cited as the biggest impediment to rolling
out HPV vaccination on a national scale [39]. In 2012, Gavi Alliance announced a price of
USD 4.50 for all Gavi Alliance-eligible countries down from USD120 per dose [40,41]. The
Alliance has offered support for national introduction of HPV vaccine for countries with dem-
onstrated ability; or to co-fund demonstration projects for two years. The demonstration proj-
ects are to guide planning and implementation of nation-wide HPV vaccination programs that
are expected to follow [41,42]. By February 2014, Gavi had approved 21 countries including
Kenya for HPV vaccine demonstration program in sub-Saharan Africa [43]. Kenya's Ministry
of Health (MOH), with the support of Gavi Alliance, started a two-year HPV vaccination dem-
onstration project in Kitui County for all girls in grade four in both public and private schools.
Ten year old girls not enrolled in school were also targeted for vaccination at health facilities
and through community outreach [44].
In this study, we assessed the knowledge of HPV vaccine and cervical cancer and the accept-
ability of HPV vaccination among primary school teachers in Kitui given the use of schools in
the campaign. We also explored facilitators and barriers to the uptake and completion of HPV
vaccination. Assessing teachers’ knowledge and acceptance of HPV vaccine to identify any
gaps that exist is useful to programmers in designing vaccination campaigns. Teachers are also
well placed to identify facilitators and barriers of vaccine uptake and opportunities that can be
used to mount other health promotion interventions during the vaccination campaign.
Methodology
Study design
This is a cross-sectional, mixed-methods approach, using both qualitative and quantitative
techniques.
Study area and population
The study was conducted in Central Division in Kitui County where the MOH has been under-
taking HPV vaccination of grade four girls since 2013. Kitui County is one of 47 administrative
regions in Kenya. The County’s geographic, social and economic challenges mirror those of a
majority of the rest of the country [45,46]. In 2013, 98% of girls in Kitui County were enrolled
in school with 8,455 girls in grade four, 94% of whom were 9–13 years old, and 166 ten-year
old girls not enrolled in school [44]. The county has about 1,100 primary schools [47]. Due to
limited resources, Kitui Central Division was selected to represent the County. The Division
has 80 primary schools (73 public and 7 private) and about 700 primary school teachers [47].
Sampling
Multi-stage sampling was done by stratifying the schools into public and private institutions
and then selecting 34 public and 3 private schools through systematic random sampling. All
teachers in selected schools were invited to participate in the study by completing a self-admin-
istered questionnaire.
Data collection
We used a self-administered structured questionnaire and focus group discussions to collect
data. The questionnaire was designed specifically for this study and did not have identifying
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data. It was in English, a language the target population understood well. Seventeen questions
were used to assess teachers’ knowledge on HPV vaccine and cervical cancer (S1 Text). These
were in ‘true/false’ format or multiple choice questions where the respondent was asked to
select one or more correct statements. The individual scores were later converted to
percentages.
Fourteen of the 37 schools were randomly selected and requested to send the head teacher,
deputy head-teacher or HPV vaccination coordinator, to one of two Focus Group Discussions
(FGDs). FGDs were held on different days in a hotel meeting room in Kitui Town. They were
conducted in English, guided by a semi-structured questionnaire and recorded on a voice
recorder.
Data management
Quantitative data was cleaned and entered into SPSS for analysis. Univariate analysis was done
by use of frequency distributions and proportions for categorical variables and descriptive sta-
tistics for continuous variables.
Bivariate analysis to test associations was done using Chi-square or Fisher’s Exact Test for
categorical variables, and t-test for continuous variables. The level of significance for all tests
was set at 5%.
FGDs recordings were transcribed and proofed to eliminate transcription and grammatical
errors. The transcriptions were loaded on to ATLAS.ti, coded into thematic groups derived
from the FGD questionnaire and actual discussions, and analyzed to identify the strength and
pattern of participants’ views.
Ethics statement
This study was approved by the Kenyatta National Hospital-University of Nairobi Ethics and
Research Committee and the National Commission for Science, Technology and Innovation
(NACOSTI). Permission to conduct the study in Kitui was granted by the Kitui County Com-
missioner, Kitui County Director of Education and head-teachers of selected schools. Written
informed consent was obtained from all participants.
Data was collected using anonymous questionnaires and no personal identifiers were ana-
lyzed or disseminated.
The 13 teachers who participated in the FGDs were reimbursed for transport cost to and
from the FGD venue (US$ 12).
Results
Respondents’ characteristics
Out of 507 teachers in 37 schools, 339 completed the survey (62% response rate); the rest were
unavailable during the time of administering the questionnaire or were unwilling to participate
in the study. Sixty percent were female and 85% were working in rural schools. Ninety-nine
percent were Christians (Catholics 44% and Protestants 55%). The average age was 40 years
(Standard deviation (SD) = 10.7). A majority of the respondents were married (77%) (Table 1).
Two FGDs with a total of 13 teachers from 13 primary schools were held. One of the 14
invited schools did not send a representative. Seven of the participants were female, three were
head-teachers, three deputy head-teachers and seven were HPV vaccination project coordina-
tors in their respective schools.
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Awareness of the HPV vaccination program
Ninety percent of the teachers were aware that the government had launched the HPV vaccina-
tion campaign targeting all grade four girls in Kitui County. Sources of information were MOH
officials (68%), fellow teachers (30%), radio (13%), Ministry of Education officials (11%), and
television (5%). Teachers in rural schools were more likely to be aware of the initiative than
teachers in urban schools (91% vs. 82%, p = 0.047). In the FGDs, many suggested that parents
and other community members should be informed about the vaccine through barazas (public
gatherings held by local leaders), churches and other social gatherings, before launching the
vaccine initiative.
Knowledge on HPV vaccine and cervical cancer
The mean score on knowledge on 17 questions asked was 48% (SD = 10.9, range = 12–84%).
Women had a higher knowledge score than men (50% vs. 46%, p = 0.002). There was no signif-
icant difference in knowledge score by school type, school location, teachers’ religion, marital
status or age.
Ninety-five percent of the participants knew that the HPV vaccine prevents cervical cancer,
but they had very little information about HPV infection and cervical cancer. Eighty-four per-
cent understood that cervical cancer is an important disease that kills many women and 61%
Table 1. Respondents' Demographic Characteristics.
Characteristic Public Schools Private Schools Total (%)
School Location Rural 276 11 287 (85%)
Urban 37 15 52 (15%)
Total 313 (92%) 26 (8%) 339
Sex Female 191 11 202 (60%)
Male 117 15 132 (40%)
Total 308 (92%) 26 (8%) 334
Age (years) Average 41 28 40 (SD = 10.7)
Age group Under 25 years 18 2 20 (6.5%)
25–34 years 62 23 85 (27.7%)
35–44 years 82 0 82 (26.7%)
45–54 years 89 0 89 (29%)
Over 55 years 31 0 31 (10.1%)
Total 282 (92%) 25 (8%) 307
Level of Education Secondary 61 0 61 (18%)
Certiﬁcate 91 22 113 (34%)
Diploma 86 4 90 (27%)
Degree 69 0 69 (21%)
Total 307 (92%) 26 (8%) 333
Religion Protestant 168 18 185 (55%)
Catholic 142 8 150 (44%)
Muslim 3 0 3 (1%)
Total 313 (92%) 26 (8%) 339
Marital Status Married 242 17 259 (77%)
Single 61 8 69 (21%)
Other 7 0 7 (2%)
Total 310 (93%) 25 (7%) 335
doi:10.1371/journal.pone.0135563.t001
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correctly responded that Pap smear is used for cervical cancer screening. However, they had no
knowledge on HPV, its transmission, signs or symptoms. Table 2 shows the proportion of cor-
rect responses to each question.
Some of the comments from FGD participants are shown below:
‘I thought it (HPV) may be inborn, the child maybe born with it, so it maybe still with the
child as she grows up and emerge later. . .’
‘I think from the word cervix, one may think it (HPV) infects the girls only because men don’t
have a cervix.’
‘All teachers should be given the same information. For instance in our district, only the head-
teacher and two other teachers were called. . . They can come and give a seminar to all the
teachers and all the parents. . .’
Acceptability of HPV vaccine
Most of the respondents (89%, n = 302/339) would allow their daughter or close relative to
receive the vaccine. Teachers in rural schools were more likely to accept the vaccine as com-
pared to their counterparts in urban schools (p = 0.01).
Teachers who were aware of the initiative were more likely to accept the vaccine (p = 0.016).
Similarly, those who accepted the vaccine had, on average, more knowledge about it than those
who declined (mean score of 49.4% and 39.7% respectively, p<0.001).
There was no significant association between acceptability and the type of school (public or
private), age, sex, level of education, length of service, religion, and marital status of the
respondents.





HPV Vaccine Protects against HIV NO 335 (99)
HPV Vaccine Protects against Breast Cancer NO 333 (98)
HPV Vaccine Protects against Cervical Cancer YES 323 (95)
Aware of HPV Vaccine exercise in Kitui County YES 300 (90)
Cervical cancer is a leading cause of cancer deaths in
women
YES 284 (84)
HPV causes Cervical Cancer YES 280 (83)
HPV can be transmitted by aerosol/droplet NO 271 (80)
Ever heard about Pap smear YES 238 (70)
Pap Smear is used for cervical cancer screening YES 261 (61)
HPV can be transmitted through Sexual Contact YES 197 (58)
There’s no need for Pap Smear after HPV vaccine NO 156 (46)
Nearly everyone infected with HPV is symptomatic NO 89 (26)
HPV infects both men and women YES 26 (8)
HPV can be transmitted through Physical Contact YES 20 (6)
HPV Vaccine Protects against Vulvar Cancer YES 18 (5)
HPV Vaccine Protects against Anal Cancer YES 7 (2)
HPV Vaccine Protects against Warts YES 3 (1)
doi:10.1371/journal.pone.0135563.t002
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About 11% (37/339) of the respondents reported that they would not allow their daughter or
close relative to receive the vaccine. More than half did not give a reason for declining while
seven of the 37 had concerns about vaccine safety. Fig 1 summarizes reasons for vaccine refusal.
All FGD participants would allow their daughter or close relative to receive the vaccine.
They also reported that some parents and teachers had reservations or had rejected the vaccine.
They cited lack of enough information and fear of side effects as the main concerns. Many of
those who had reservations later accepted the vaccine once they got more information about it,
as noted by an FGD participant quoted below:
‘There are some (parents) who would come and ask us about it, we would explain to them
why the vaccine is given, and then after explanation, they would accept that their children be
given the vaccine.’
The participants did not identify any particular side effects that they feared the vaccine
might cause. Only one school reported actual side effects where two girls felt dizzy. This favor-
able safety profile reduced their fears for subsequent doses.
Another concern was fear among some parents and some teachers that the vaccine was a
contraceptive. Most (12/13) FGD participants had heard about this concern but no one could
identify its origin. They reported that it is a fear that cuts across most vaccinations and one that
could be allayed by proper information from health officials.
Respondents’ attitudes towards the HPV vaccine
Respondents’ attitudes were measured on a scale of 1–3 (agree, neutral and disagree). Nearly
all respondents (98%) expressed interest to know more about the HPV vaccine, 93% supported
school-based vaccine delivery and 79% felt that the vaccine was safe (Fig 2).
Barriers to successful implementation of the vaccination program:
Out of all respondents, 70% (237/339) cited at least one barrier that hindered the success of the
vaccination project. A third of all respondents cited lack of information as a major barrier to
HPV vaccination. Other prominent barriers were poor accessibility of the region (16%), pupil
absenteeism (4%) and fear of side effects (8%).
Fig 1. Reasons for not allowing daughter to receive HPV vaccination. Shows reasons why teachers
would not allow a daughter to receive HPV vaccine.
doi:10.1371/journal.pone.0135563.g001
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Less prominent barriers included negative attitude towards the vaccine by some parents or
teachers, religious beliefs, refusal to be vaccinated by the girls or their parents, poor organiza-
tion and planning, inadequate means of transport for MOH staff and dose delays past the
expected vaccination dates (each cited by less than7% of the respondents) (Fig 3).
The participants reported that accessibility was a major issue due to poor road network and
vastness of the County. They also observed that MOH vaccinators did not have adequate
means of transport to traverse the County.
Some cited cultural and religious beliefs that were against vaccinations and fear of side
effects as barriers too. One of the FGD participants made the following statement:
‘We have some religions that don’t allow modern medicine, so the government should come in
and decide what to do with the parent.’
Fig 2. Participants’ responses to various statements. Shows participants’ responses on a Likert scale:
The black color represents those who ‘agreed’, the light grey color represents the proportion who were
‘neutral’ and the dark grey represents those who ‘disagreed’ with the statement.
doi:10.1371/journal.pone.0135563.g002
Fig 3. Barriers to the HPV vaccination project. Shows barriers to the HPV vaccination project in Kitui
County as reported by Primary School teachers.
doi:10.1371/journal.pone.0135563.g003
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Disruption of school activities
Most of the respondents (75%, n = 244/327) felt that the exercise only minimally disrupted the
school activities. A fifth felt there was no disruption at all, while 6% thought the exercise caused
severe disruption. Comparing teachers who thought there was at least some disruption (81%)
and those that reported no disruption (19%), the latter were more likely to accept the vaccine
(p = 0.014).
Consenting to vaccinate
FGD participants felt that it was desirable for the parent and girl to give consent before vacci-
nation. However, most (10/13) FGD participants felt that all girls should be vaccinated whether
the parent/guardian agrees or not. Many felt that since the government had initiated the vac-
cine, it was beneficial to the girls and should be given by all means including enforcement by
the police. Citing an example, a few mentioned a religion called ‘Kavonokya’ whose followers
do not take any form of modern medicine and are often forced to allow their children to receive
the regular vaccines. One of the FGD participants made the following remark:
‘. . .I had another case unrelated to HPV vaccine. In my former school a child from ‘Kavono-
kya’ religion was sick. The mother had died of anemia and the child was so sick he couldn’t
concentrate [in class]; we had to force the child to go to hospital. So for the benefit of the child
we have to force [vaccination].’
Discussion
The aim of this study was to assess the knowledge and acceptability of HPV vaccine among pri-
mary school teachers in Kitui County Central Division and explore their views on facilitators
and barriers of HPV vaccination following the launch of the first HPV pilot program in Kenya
by the MOH. We found high levels of awareness (90%) and acceptability (89%) of HPV vac-
cine, and a moderate level of knowledge about the vaccine, HPV, and cervical cancer among
the teachers (48%). Teachers, together with adolescents, parents and healthcare professionals,
are key facilitators to successful vaccination programs [16,19,21,29,48]. Our findings on aware-
ness of HPV vaccine concur with those from studies conducted after an awareness campaign in
other parts of the world. Levels of 91% awareness among parents of adolescent daughters have
been reported in North America [49] and France [50]. High levels of awareness of HPV vaccine
among adolescent women, parents and nurses have also been reported in Cameroon following
an education campaign [20,51,52] although most studies in SSA report generally low levels of
awareness among key facilitators [21,53]. In a qualitative study in Tanzania, none of the
parents, teachers and girls interviewed knew of the vaccine [19]. Similarly, in another study on
women attending two hospitals in Kisumu, Kenya, none of the women had heard of the HPV
vaccine [25]. The high level of awareness among teachers in our study was most likely due to
the ongoing HPV vaccination campaign in the County. Teachers in rural schools were more
likely to be aware of the vaccination initiative than their counterparts in urban schools. This is
likely because rural schools had fewer teachers per school than urban schools making it easier
to disseminate information on the vaccine by word of mouth.
Findings on acceptability are consistent with results from several studies in SSA and many
other parts of the world showing high acceptability of the HPV vaccine or willingness to rec-
ommend it to a friend or relative. Previous studies in the United Arab Emirates, Argentina,
Ghana, Cameroon, Tanzania, Uganda and Kenya reported high acceptability levels ranging
from 75% to 99% [17,19,20,53–56].
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A recent study in Nairobi reported that 69% of women knew that Pap smear testing is used
to screen for cervical cancer [17], similar to 70% in our study. However, very few women in
Kenya actually access screening services [17]. More than half of the teachers in this study
(56%) do not know that screening by Pap smear is necessary even after one has received the
HPV vaccine. Currently available bivalent and quadrivalent HPV vaccines which cover two
oncogenic HPV serotypes (HPV 16 and 18) prevent about 70% of cervical cancer cases [57,58]
and a nonavalent vaccine which covers five additional oncogenic HPV genotypes (HPV 31, 33,
45, 52 and 58) prevents up to 90% of all cervical cancer [59]. In addition, the vaccines are not
effective if administered after infection has occurred. Therefore, vaccination against HPV does
not obviate the need for cervical cancer screening.
The fact that female teachers in this study had more knowledge on HPV and cervical cancer
than male teachers (50% versus 46%, p = 0.002) may be due to a perception that HPV affects
women only. This is similar to findings of a study among secondary school teachers in Malaysia
where awareness of HPV vaccine was higher in female teachers than in males (54% versus
33%) [48].
Noted barriers to HPV vaccination program include insufficient information, poor road
access and pupil absenteeism. Kitui County has a poor road network with only 0.3% of roads
paved [46], and is reflective of many other areas in Kenya. This creates challenges in accessing
populations and transporting vaccines and health personnel in rural areas [60]. Pupil absentee-
ism on the vaccination days is also noted as a major barrier in a study in Tanzania [16]. This
shows that good record keeping and tracking will be required to reach girls who may transfer
or drop out of school before completing the three vaccine doses. Poor transport system and
absenteeism calls for continued effort towards innovative delivery strategies and vaccine design
to create heat-stable, single-dose HPV vaccines. Teachers’ concerns about side effects in our
study are minimal (11%) compared to 35% of males in a study in Tanzania where head teachers
in private schools would not allow vaccination out of fear of parents [19].
School-based delivery is the most preferred method for reaching girls with the HPV vaccine
and has been used in Rwanda, South Africa, Tanzania and Uganda with high levels of uptake
[21, 26]. Other studies in Botswana [61] and Ghana [46] recommended schools as the ideal
venue. However few studies have assessed teachers’ perceptions about HPV vaccine. To the
best of our knowledge, this is the only study done in Kenya that assesses teachers’ knowledge
on HPV vaccine. Assessing and securing teachers’ support will be essential to successful vac-
cine implementation in Kenya.
Due to resource constraints, this study was conducted in one of 20 divisions in Kitui
County. Although there are no discernible differences (in socio-economic levels, urbanicity,
ethnicity or school distribution) in other divisions, collecting data from selected schools across
the entire County may have provided a more complete picture on teachers’ views for national
utility. Willingness to recommend the vaccine to a daughter or close relative was used as a
marker for vaccine acceptability. This may not necessarily reflect the real picture on uptake of
the vaccine at the time of administration. Another limitation was the fact that our question-
naire was not validated before use. In addition, the significant number (38%) of teachers who
did not participate in the study may be a potential cause of bias. The main strength of this
study was the use of qualitative methods to provide further insight into quantitative data.
Conclusion
Our study shows that teachers have embraced the school-based approach as a mode of giving
adolescent girls the HPV vaccine. Future campaigns should leverage this support by teachers.
The study highlights the gap in knowledge on cervical cancer and HPV vaccines reported by
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similar studies. It also shows that insufficient knowledge on HPV vaccine may reduce the will-
ingness of teachers to allow their daughters to be vaccinated or recommend the vaccine to oth-
ers. There is need to address vaccine safety concerns and educate the community that HPV is a
sexually transmitted infection that affects both men and women. As the country prepares to
launch a nation-wide HPV vaccination for adolescent girls, one of the key investments should
be in dissemination of information on HPV, HPV vaccine and cervical cancer. Effective ways
of educating teachers, parents and girls are therefore needed. Because schools are likely to be
the chosen vehicles/venues for delivery the first step should be recruitment and training of
teachers to act as vaccine champions so as to educate their colleagues, parents and targeted
girls. In addition, community mobilization strategies such as targeting audiences in social and
religious gatherings as well as use of mass media may be viable strategies to disseminate infor-
mation on HPV vaccine and cervical cancer to facilitate successful implementation.
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